中国肺癌杂志2011，Vol.14Issue(11)：874-879,6.DOI:10.3779/j.issn.1009-3419.2011.11.08
个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述
Current Status and Future Direction of Multi-targeted Drugs in the Era of Personalized Therapy -Overview of Advances in Multi-targeted Therapy in Non-small Cell Lung Cancer
周彩存1
作者信息
- 1. 200433 上海,同济大学医学院附属上海市肺科医院肿瘤科
- 折叠
摘要
Abstract
Multi-targeted tyrosine kinase inhibitors (TKIs) play important roles in the treatment of non-small cell lung cancer (NSCLC). Recently, results of several large phase III studies have been published, showing bittersweet efficacy of multi-targeted TKIs. In the era of personalized therapy, optimal use of multi-targeted TKIs is worthy of further investigation. In this review, we summarized current clinical development and future direction of multi-targeted TKIs in NSCLC.关键词
肺肿瘤/多靶点药物/舒尼替尼/索拉非尼/凡德他尼/CrizotinibKey words
Lung neoplasms/ Multi-targeted tyrosine kinase inhibitor/ Sunitinib/ Sorafenib/ Vandetanib/ Crizotinib分类
医药卫生引用本文复制引用
周彩存..个体化治疗时代多靶点药物究竟何去何从——多靶点药物治疗非小细胞肺癌最新临床进展综述[J].中国肺癌杂志,2011,14(11):874-879,6.
